XPEL screens as a profitable small-cap quality name after a record Q2 2026 revenue print, expanding international demand and a balance sheet that does not appear to constrain the thesis. The valuation does not assume a deep dislocation: the base case fair value is $47.50, or about 8% above the last verified close, so the investment case depends on continued execution rather than multiple expansion alone.
Peer reference 13.0x EV/EBITDA plus 10% for XPEL's higher growth and margin profile gives about 14.3x, rounded to 14.5x. Implied multiple: (FV equity $1.31B - $25M net cash - $15M option value + $9.7M reserves) / $88M FY2026E EBITDA = 14.5x. Sensitivity: +/-2x multiple changes FV by roughly +/-$6.40/sh. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Core operating value | $88M FY2026E EBITDA x 14.5x EV/EBITDA / 27.56M shares | +46.30 |
| Net cash / low leverage benefit | Approx. $25M net cash equivalent / 27.56M shares | +0.91 |
| Window film growth option | 20% probability x $75M incremental platform value from record $32.5M Q2 window-film revenue / 27.56M shares | +0.54 |
| Share-count effect | Broadly flat shares; no material buyback accretion modeled | +0.00 |
| Manufacturing execution reserve | $8.3M reserve for San Antonio/China plant ramp friction / 27.56M shares | -0.30 |
| Trade and regional demand reserve | $1.4M residual reserve for tariff and Middle East / India softness / 27.56M shares | -0.05 |
| FV base case | Exact sum: 46.30 + 0.91 + 0.54 + 0.00 - 0.30 - 0.05 | 47.40 |
Interpretation: the short base is large enough to increase volatility around earnings, but not high enough to justify the thesis by itself. It mainly signals disagreement around the durability of growth, China execution and valuation premium.
| Item | FY2024 | FY2025 | TTM 2026 | FY2026E | Guidance / note |
|---|---|---|---|---|---|
| Revenue | $420M | $476M | $489.8M | $545M | Estimate, supported by record Q2 run-rate |
| EBITDA | $66M | $75M | $78.4M | $88M | Estimate using 16.1% EBITDA margin |
| Net income | $44M | $48M | $53.0M | $59M | Q2 profit $18.0M |
| Gross margin | ~42% | ~42% | 42.5% | 43.0% | Manufacturing benefits not fully modeled until 2027 |
| Free cash flow margin | ~10% | ~11% | 11.9% | 10.5% | Tempered for working capital and facility investment |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 124.8 | N/D | N/D | 117.4 | 143.1 |
| Gross margin % | N/D | N/D | N/D | N/D | ~42.5 |
| Net income ($M) | 16.3 | N/D | N/D | N/D | 18.0 |
| EPS ($) | N/D | N/D | N/D | 0.37 | 0.61 |
Business model - premium protective surfaces
Paint protection film ~$360-$390M FY2026E revenue base ramping Core product family and brand anchor. Demand depends on premium auto customization, installer productivity and pricing discipline. Window film $32.5M Q2 2026 revenue ramping Record Q2 level makes this the clearest second growth vector. Sustained mix improvement would support the bull case. Software, tools and services N/D - embedded channel revenue to prove DAP patterns, training and fulfillment support reduce switching but are not yet disclosed as a standalone high-multiple segment.
Legal, regulatory and risk analysis
SWOT analysis
- +Premium brand in protective films.
- +High gross margin and ROE profile.
- +Q1 and Q2 2026 earnings/revenue beats.
- +Low leverage reduces financing risk.
- −Upside is modest at the verified price.
- −Valuation remains above commodity auto-supplier levels.
- −Some revenue data by segment remains incomplete in public snippets.
- −Small-cap liquidity can magnify moves.
- →Window film scale can diversify the mix.
- →China local production can support margin and supply resilience.
- →Mid-2027 plant benefits may reset earnings power.
- →Short interest could amplify a positive earnings reset.
- !Auto cycle weakness.
- !Tariff or input-cost pressure.
- !Competitive price pressure from lower-cost film suppliers.
- !Multiple compression if growth falls below premium expectations.
Summary by assessment area
- XPEL's margin profile, profitability and brand/channel structure justify a quality label.
- The balance sheet does not force a dilution or distress discount.
- The base FV offers only about 8% upside from the verified close.
- The stock needs clean Q3/Q4 execution to justify a larger premium.
- Q3 earnings, manufacturing progress and 2027 margin commentary are the highest-value watch items.
- Analyst target cross-check supports upside but is not used as the valuation anchor.
Sources: price/market data - StockAnalysis XPEL overview and Investing.com XPEL quote/consensus pages, last verified close 2026-07-28 at $43.98; official and recent results - Zacks/Yahoo Finance Q1 2026 EPS/revenue beat and San Antonio Express-News Q2 2026 earnings coverage; annual/TTM financial history - StockAnalysis statistics and valuation pages; market cap/shares/52W - StockAnalysis and CompaniesMarketCap snapshots; short interest - MarketBeat July 2026 short-interest page; analyst target - StockAnalysis/Investing.com consensus target reference around $51.67, latest public snapshot reviewed in July/August 2026; governance/insider/class action - reviewed web search did not identify a material class action, SEC investigation or short-seller report in the last 12 months, insider Form 4 detail N/D pending primary filing reconciliation; peer comparables - DORM, GNTX, LKQ and FOXF market valuation snapshots from StockAnalysis/Yahoo/Investing-style sources. Market data - last verified close 2026-07-28. This document is for informational purposes only and does not constitute financial or investment advice.